More News

Transpharmation acquiring OrganoTherapeutics

Jim Cornall -
Transpharmation Ltd. has announced the acquisition of OrganoTherapeutics SARL, a provider of patient-derived organoid technologies that advance the discovery...

Astrosalva Therapeutics born to beat Alexander disease and cALD

Jim Cornall -
Astrosalva Therapeutics, Inc. has launched to develop treatments for Alexander disease and the cerebral form of adrenoleukodystrophy (cALD). Unravel Biosciences,...

Ageing study shows promising effects of supplement on vascular health biomarkers

Jim Cornall -
A multi-component nutritional supplement has been found to improve markers of vascular health, in a randomised controlled trial led...

New transport pathway shows promise for brain drug delivery

Jim Cornall -
Researchers at the University of Eastern Finland have identified a transporter protein with the potential to open new avenues...

MEPSGEN debuts system for small-volume nanoparticle formulation

Jim Cornall -
MEPSGEN US, Inc. has launched the NanoCalibur Mini, an automated system for small-volume nanoparticle formulation designed for early-stage drug...

Positive results from extensive-stage small cell lung cancer study

Jim Cornall -
Shanghai Henlius Biotech, Inc has announced positive results from ASTRIDE, a randomised, descriptive, open-label, US study of serplulimab (in...

ALLOX raises $10.5m to scale allosteric drug discovery platform and build pipeline

Jim Cornall -
ALLOX, a biotechnology company developing a high-throughput, experimental-first platform to discover and exploit allosteric sites and other regulatory regions...

Worm study may have implications for Alzheimer’s and Huntington’s

Jim Cornall -
A new study has discovered that reducing a cellular process called UFMylation helped worms better cope with toxic protein...

Blocking immune cell signals could make brain tumours easier to remove

Jim Cornall -
In a new study published in Cancer Cell, researchers at VIB-KU Leuven in Belgium reduced the spread of glioblastoma...

Exogenus Therapeutics leads €13m consortium to advance new secretome-based therapy for osteoarthritis

Jim Cornall -
The ExoCordOA consortium has launched a five-year, €13m project, funded by Horizon Europe, to advance extracellular vesicle-enriched secretome therapies...

Base to Base biotech podcast 82: Restoring blood flow to the heart and tackling HHT

Jim Cornall -
This week, we have a conversation with Philip Brainin, CEO of Isomab, about restoring blood flow to the heart,...

Early results from “encouraging” pancreatic cancer study

Jim Cornall -
ImPact Biotech has announced the successful completion of treatment in part A of its phase 1 clinical trial in...

Familiar Therapeutics launches to close gap between human and veterinary medicine

Jim Cornall -
Familiar Therapeutics has launched with $5m in seed funding to bring the advances of modern human medicine to dogs...

Scientists create white blood cell with memory of how to fight off winter flu bugs

Jim Cornall -
Researchers at the University of Southampton in the UK are developing killer cells, a type of white blood cell,...

Topline results from metastatic breast cancer phase 3 trial

Jim Cornall -
BioNTech SE and DualityBiologics (Suzhou) Co., Ltd. have announced that the DYNASTY-Breast02 global phase 3 clinical trial met its...

Updated prostate cancer results show anti-tumour activity

Jim Cornall -
AdvanCell has announced updated results from the TheraPb phase 1 clinical trial evaluating ADVC001, an investigational lead-212 PSMA-targeted alpha...

Gesynta Pharma continues endometriosis work

Jim Cornall -
Gesynta Pharma AB has completed enrolment in NOVA, its phase 2 clinical proof-of-concept and dose-finding trial. With 213 patients...

First-in-human circular RNA therapy for radiation-induced xerostomia

Jim Cornall -
RiboX Therapeutics has announced the publication of a peer-reviewed Research Letter in The New England Journal of Medicine (NEJM)...

Data show unresectable patients becoming eligible for surgery

Jim Cornall -
Brenus Pharma has announced first data from the phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were...

Personalised cancer vaccine with immunotherapy reduces melanoma recurrence after surgery

Jim Cornall -
Adding a personalised mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or...

AI drug choices may cost millions

Jim Cornall -
Large language models (LLMs), such as ChatGPT and Claude, are increasingly being used to provide health information to the...